HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
|Articles|May 7, 2012
FDA, NIH Respond to Charges of Lax Oversight
Advertisement
The FDA and the National Institutes of Health don't agree with allegations that sponsors of clinical trials are not adhering to a federal law that requires public reporting of clinical trial data within one year of completion.
Both agencies wrote letters to Congress disputing charges leveled against them in an analysis published in January in BMJ that found that neither government-funded nor privately-funded studies for pre-approved drugs were being reported in a timely manner, according to an article published online this week in Nature.
Read the full story:
Source: MedPage Today
Advertisement
Related to this article
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
Subcutaneous mosunetuzumab plus polatuzumab vedotin boosts responses in relapsed large B-cell lymphoma, helping community oncology care.
Using baseline samples from 177 patients in the VISION/HO141 trial, researchers built a functional prognostic model for CLL that outperformed the CLL-IPI.
The Franklin County death is under state review as Pennsylvania's measles outbreak passed 1100 cases and 219 hospitalizations.
Among 4378 Spanish registry patients, dyshidrotic eczema was less tied to occupation than other hand eczema.
New non-CF bronchiectasis in Medicare is tied to high health care use and $8998 PPPM FFS spending; prevalence is highest in older women.
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
NPC researchers examined questions about how these policies could affect patients, pharmacies, and providers.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
FDA Approves First Treatment for BCG-Unresponsive Bladder Cancer
3
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
4
Admilparant Phase 3 ALOFT-IPF Trial Meets Primary End Point in IPF
5